| Trial ID: | L6178 |
| Source ID: | NCT01593215
|
| Associated Drug: |
Yohimbine
|
| Title: |
Randomized Study of Yohimbine Treatment for Type 2 Diabetes Patients Carrying a Specific Genetic Risk Variant
|
| Acronym: |
YOH1
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01593215/results
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Yohimbine
|
| Outcome Measures: |
Primary: Insulin Secretion, insulin secretion will be measured (nMole) in response to an oral glucose tolerance test. Patients will receive the capsules 1 h before the glucose test, and the insulin levels 30 minutes after the oral glucose will be used as a primary outcome measure. The insulin levels at the highest tolerated dose of yohimbine will be used., 30 minutes after oral glucose | Secondary: Glucose, Plasma glucose will be measure (mMole) in response to an oral glucose tolerance test. Patients will receive the capsules 1 h before the glucose test, and the glucose levels 30 minutes after the oral glucose will be used as a secondary outcome measure. The glucose levels at the highest tolerated dose of yohimbine will be used., 30 minutes after oral glucose
|
| Sponsor/Collaborators: |
Sponsor: Anders Rosengren, MD PhD | Collaborators: Region Skane|Lund University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
50
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2012-05
|
| Completion Date: |
2014-10
|
| Results First Posted: |
2015-01-09
|
| Last Update Posted: |
2015-01-09
|
| Locations: |
Skanes Universitetssjukhus, Malmo, Skane, 20502, Sweden
|
| URL: |
https://clinicaltrials.gov/show/NCT01593215
|
